<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS141076</article-id>
<article-id pub-id-type="doi">10.1101/2021.12.03.471068</article-id>
<article-id pub-id-type="archive">PPR428751</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The <italic>Petasites hybridus</italic> CO<sub>2</sub>-extract (Ze 339) blocks SARS-CoV-2 replication <italic>in vitro</italic>
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Urda</surname>
<given-names>Lorena</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kreuter</surname>
<given-names>Matthias Heinrich</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Drewe</surname>
<given-names>Jürgen</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boonen</surname>
<given-names>Georg</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Butterweck</surname>
<given-names>Veronika</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Klimkait</surname>
<given-names>Thomas</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department Biomedicine, University of Basel, Petersplatz 10, 4051 Basel, Switzerland</aff>
<aff id="A2">
<label>2</label>Max Zeller &amp; Söhne AG, Medical Department, Seeblickstrasse 4, 8590 Romanshorn, Switzerland</aff>
<author-notes>
<corresp id="CR1">
<bold>Corresponding Author:</bold> Prof. Dr. Thomas Klimkait, University of Basel, Department Biomedicine, Petersplatz 10, 4051 Basel, Tel.: +41 612073272, <email>thomas.klimkait@unibas.ch</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>07</day>
<month>02</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="preprint">
<day>07</day>
<month>12</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">The coronavirus disease 2019 (COVID-19), caused by a novel coronavirus (SARS-CoV-2), has spread worldwide, affecting over 250 million people and resulting in over five million deaths. Antivirals that are effective are still limited. The antiviral activities of the <italic>Petasites hybdridus</italic> CO<sub>2</sub>-extract Ze 339 were previously reported. Thus, to assess the anti-SARS-CoV-2 activity of Ze 339 as well as isopetasin and neopetasin as major active compounds, a CPE- and plaque reduction assay in Vero E6 cells was used for viral output. Antiviral effects were tested using the original virus (Wuhan) and the Delta variant of SARS-CoV-2. The antiviral drug remdesivir was used as control. Pre-treatment with Ze 339 in SARS-CoV-2 infected Vero E6 cells with either virus variant significantly inhibited virus replication with IC<sub>50</sub> values of 0.10 and 0.40 μg/mL, repectively. The IC<sub>50</sub> values obtained for isopetasin ranged between 0.37-0.88 μM for both virus variants, that of remdesivir between 1.53-2.37 μM. In conclusion, Ze 339 as well as the petasins potently inhibited SARS-Cov-2 replication <italic>in vitro</italic> of the Wuhan and Delta variants. Since time is of essence in finding effective treatments, clinical studies will have to demonstrate if Ze339 can become a therapeutic option to treat SARS-CoV-2 infections.</p>
</abstract>
<kwd-group>
<kwd>SARS-CoV-2</kwd>
<kwd>COVID-19</kwd>
<kwd>anti-COVID-19</kwd>
<kwd>antiviral</kwd>
<kwd>Delta variant</kwd>
<kwd>
<italic>Petasites hybridus</italic>
</kwd>
<kwd>isopetasin</kwd>
<kwd>cytotoxicity</kwd>
<kwd>selectivity index</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p id="P2">COVID-19 (<underline>co</underline>rona<underline>v</underline>irus disease 20<underline>19</underline>) first occurred in China end of 2019 and has since then spread around the globe, causing more than 5 million deaths [<xref ref-type="bibr" rid="R1">1</xref>]. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is transmitted mainly via droplets and aerosols (for review see [<xref ref-type="bibr" rid="R2">2</xref>]). Infectivity begins one to several days before symptom onset, and even asymptomatically infected individuals can transmit the virus [<xref ref-type="bibr" rid="R2">2</xref>]. The disease affects the upper respiratory tract and lungs, heart, liver, gastrointestinal tract, and other organs, but the majority of infections remains asymptomatic, and patients develop only mild symptoms [<xref ref-type="bibr" rid="R3">3</xref>]. However, severe courses of COVID-19 are commonly accompanied by severe immune activation [<xref ref-type="bibr" rid="R4">4</xref>]. Observations include lymphocytopenia, an increase in neutrophils, and increased serum levels of IL-1β, IL-2, IL-4, IL-6, IL-10, TNF-α, and interferon-γ [<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>]. This cytokine response (also referred to as ‘cytokine storm’) is associated with cellular injury, which in turn is reflected in increased serum levels of lactate dehydrogenase (LDH), cardiac and hepatic enzymes, and the activation of coagulation and fibrinolysis with markedly increased plasma levels of D-dimers, among others [<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>]. In acute respiratory distress syndrome (ARDS) due to COVID-19, alveolar injury with desquamation of pneumocytes, hyaline membranes, and lymphomonocytic infiltrates has been described [<xref ref-type="bibr" rid="R7">7</xref>–<xref ref-type="bibr" rid="R9">9</xref>]. Lymphocytic endothelitis and apoptosis of endothelial cells in lungs, kidneys, and small intestine have also been observed [<xref ref-type="bibr" rid="R10">10</xref>]. The hyperinflammatory host-response caused by an overproduction of early response proinflammatory cytokines (e.g. TNFα, IL-6, IL1-β) leads to multiorgan thrombotic complications, hyperpermeability, organ failure and death [11, 12]. For severe cases, several therapeutic strategies are currently being explored targeting the hyperinflammation caused by an overactive cytokine response (for review see [<xref ref-type="bibr" rid="R13">13</xref>]). However, a breakthrough in drug therapy has not yet been achieved, although the first candidates for an oral therapy have reached the approval process [<xref ref-type="bibr" rid="R14">14</xref>]. Among those is Paxlovid™ with the active ingredient PF-07321332 which is the first oral antiviral drug available desigend to combat SARS-CoV-2. PF-07321332 is an antiviral medication developed by Pfizer that inhibits the activity of 3C-like protease (3CL<sup>PRO</sup>) required for virus replication. Without the activity of the SARS-CoV-2 3CL<sup>PRO</sup>, nonstructural proteins (including proteases) cannot be released to perform their functions, thereby inhibiting viral replication [<xref ref-type="bibr" rid="R15">15</xref>]. Paxlovid™ also contains a modest dose of ritonavir (a Ser-protease inhibitor and inhibitor of cytochrome P450 3A4), which delays the breakdown of PF-07321332, allowing it to stay in the body for longer at virus-inhibiting levels. In COVID-19 patients, the drug is likely to lower the rates of hospitalization [<xref ref-type="bibr" rid="R16">16</xref>]. Another drug currently under investigation is Molnupiravir, a Ridgeback Biotherapeutics product licensed by Merck, which increases the frequency of spontaneous alterations in the viral RNA and thus, inhibits SARS-CoV-2 replication [<xref ref-type="bibr" rid="R14">14</xref>].</p>
<p id="P3">In the numerous clinical trials that are currently being conducted worldwide, only remdesivir and dexamethasone have shown partial efficacy in combating hyperinflammatory stages of severe COVID-19 [<xref ref-type="bibr" rid="R17">17</xref>–<xref ref-type="bibr" rid="R24">24</xref>]. Furthermore, monoclonal antibodies, which block coronavirus surface proteins and reduce SARS-CoV-2 infection, are the only type of therapy approved in the United States for early-stage COVID-19. However, the high cost (about $2000 per dose, currently subsidized by the federal government in the United States), scarcity, and necessity to infuse or inject them have hindered their usage, especially in the developing world [<xref ref-type="bibr" rid="R14">14</xref>]. Therefore, COVID-19 therapies that are both affordable and simple to use are critically needed. Recent studies suggest that in addition to cytokines, leukotrienes (LTs) could also be considered as therapeutic targets since they further contribute to the hyperinflammation in severe COVID-19 cases [<xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R29">29</xref>]. The involvement of LTs in severe COVID-19 cases has been shown in some recent studies, confirming high LT levels in the bronchoalveolar lavage fluid of COVID-19 patients [<xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R31">31</xref>].</p>
<p id="P4">Leukotrienes (LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>) are peptide-conjugated lipids that are prominent products of activated eosinophils, basophils, mast cells and macrophages [<xref ref-type="bibr" rid="R32">32</xref>–<xref ref-type="bibr" rid="R34">34</xref>]. They are generated <italic>de novo</italic> from cell membrane phospholipid-associated arachidonic acid via the 5-lipoxygenase pathway. Known to cause contraction of bronchial smooth muscle, leukotrienes have been recognized as potent inflammatory mediators that initiate and propagate a diverse array of biologic responses including macrophage activation, mast cell cytokine secretion and dendritic cell maturation and migration [<xref ref-type="bibr" rid="R35">35</xref>, <xref ref-type="bibr" rid="R36">36</xref>]. Thus, it is likely that LTs could play an important role in the hyperimmune/inflammatory storm observed in COVID-19 [<xref ref-type="bibr" rid="R29">29</xref>]. It has been proposed recently that montelukast, a leukotriene receptor antagonist, and zileuton, a 5-lipoxygenase inhibitor, might be possible treatment options for mild or even severe stages of COVID-19 [<xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R29">29</xref>], especially when given in combination [<xref ref-type="bibr" rid="R27">27</xref>].</p>
<p id="P5">Ze 339, a lipophilic subcritical CO<sub>2</sub>-extract prepared from the leaves of <italic>Petasites hybridus</italic> (L.) P.G. Gaertn., B Mey., &amp; Scherb (Asteraceae), is an herbal treatment licensed in Switzerland and other countries used to treat allergic rhinitis [<xref ref-type="bibr" rid="R37">37</xref>]. Ze 339 has been demonstrated to inhibit leukotriene synthesis in various <italic>in vitro</italic> and ex <italic>vivo</italic> studies; the inhibition was solely attributable to the sum of petasins [<xref ref-type="bibr" rid="R38">38</xref>–<xref ref-type="bibr" rid="R41">41</xref>]. In particular, in human macrophages activated with platelet-activating factor (PAF), Ze 339 blocked Cys-LT and LTB4 synthesis, and further decreased PAF-and complement peptide C5a-mediated Cys-LT synthesis in eosinophils and LTB4 synthesis in neutrophils. In human eosinophils and neutrophils, the effects of the positive control zileuton, an orally active inhibitor of LT production, were similar to Ze 339 [<xref ref-type="bibr" rid="R40">40</xref>]. Furthermore, petasin and its isomers ehxibited no differences in their ability to inhibit 5-lipoxygenase (5-LOX), leukotriene C4 (LTC4) synthase and leukotriene A4 (LTA4) hydrolase, according to a recent study [<xref ref-type="bibr" rid="R38">38</xref>]. The authors of this study also showed that the extract matrix had no influence on the leukotriene inhibitory effects of the petasins. In addition to these mechanistic <italic>in vitro</italic> data, leukotriene levels decreased significantly in nasal lavage fluids of patients suffering from allergic rhinitis after 5 days of oral treatment with Ze 339 [<xref ref-type="bibr" rid="R39">39</xref>]. It is noteworthy to mention that Ze 339 also inhibited pro-inflammatory cytokine and chemokine response in human nasal epithelial cells after stimulation with viral mimics [<xref ref-type="bibr" rid="R42">42</xref>]. The authors also showed that the pro-inflammatory cytokine/chemokine response to bacteria was not inhibited by Ze 339. These findings highlight the potential of Ze 339 as a promising candidate for the treatment of a virally induced exacerbation of inflammatory processes in the upper airways. Based on the findings mentioned above, it was the aim of the present study to investigate if Ze 339 would also have an impact on SARS-CoV-2 replication <italic>in vitro.</italic> A cellular infection system was used to assess the ability of the substance(s) to interfere with cellular responses to and infection with SARS-CoV-2 virus variants.</p>
</sec>
<sec id="S2" sec-type="materials | methods">
<label>2</label>
<title>Materials and Methods</title>
<sec id="S3">
<label>2.1</label>
<title>Compounds and Extract</title>
<p id="P6">Ze 339 is a subcritical CO<sub>2</sub>-extract prepared from the leaves of <italic>P. hybridus</italic> (drug-extract ratio 50-100:1) and was manufactured by Max Zeller Söhne AG, Switzerland using a patented procedure [<xref ref-type="bibr" rid="R43">43</xref>, <xref ref-type="bibr" rid="R44">44</xref>]. One coated film tablet contains 17-40 mg of Ze 339 and is standardized to 8 mg petasins. The herein used Ze 339 batch 150056 contained 37.7% total petasins and 27.2% fatty acids. The remaining 35.1% contained other constituents such as essential oils, sterols, minerals and vitamins. Pyrrolizidine-alkaloids have been quantitatively removed in the manufacturing process using an online-adsorption-technology and were no longer detectable (limit of quantification &lt;2 ppb). A characteristic GC-chromatogram is shown in <xref ref-type="supplementary-material" rid="SD1">Supporting Figure S1</xref>. The extract was dissolved in a mixture of DMSO/H<sub>2</sub>O (50:50); a stock solution of 2 mg/ml was prepared and further diluted with assay buffer (DMEM, 2% FBS, 1%PS) to the final concentrations between 0.001 – 20 μg/m. Petasin (purity 92.82%), neopetasin (purity 94.49%) and isopetasin (purity 96.23%) were purchased from HWI Pharma Services GmbH, Ruelzheim, Germany. Stock solutions of petasin, isopetasin and neopetasin (10 mg/ml, respectively) were prepared using a DMSO/H<sub>2</sub>O (90:10) mixture and further diluted with assay buffer (DMEM, 2% FBS, 1%PS) to reach the final concentrations for testing (0.001 - 20 μg/ml, corresponding to 3.16 nM – 63 μM). Remdesivir (purity ≥98%) was purchased from Adipogen AG, Liestal, Switzerland. A 500 μM stock solution was prepared and further diluted with assay buffer to the desired concentrations (0.002-50 μM). To avoid cytotoxicity, the final DMSO concentration in all cellular experiments did not exceed 0.5%.</p>
</sec>
<sec id="S4">
<label>2.2</label>
<title>Cells</title>
<p id="P7">Vero E6 cells had been provided by the group of V. Thiel, Berne, Switzerland. Cells were cultivated in DMEM, high glucose, media (Gibco, Thermofisher AG, Allschwil, CH) and supplemented with Pen/Strep (1%, Bioconcept, Allschwil, CH) and 2% fetal bovine serum (FBS, Gibco, Thermofisher), at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>.</p>
</sec>
<sec id="S5">
<label>2.3</label>
<title>Viral reconstitution</title>
<p id="P8">Virus stocks of the initial Wuhan strain of SARS-CoV-2 were provided by G. Kochs, University of Freiburg, D, (SARS-CoV_FR-3) and by EVAglobal virus archive, (SARS-CoV-2 strain /NL/2020 - AMS). Virus stocks were propagated in a Biosafety level 3 facility by infecting Vero E6 cells at a multiplicity of 0.1 and harvesting culture supernatant on day 3. Cell-free virus in culture supernatant was quantified by RT-PCR of the S-gene RDB region [<xref ref-type="bibr" rid="R45">45</xref>] and by plaque titration. Viral titers were determined by plaque assays in Vero cells.</p>
</sec>
<sec id="S6">
<label>2.4</label>
<title>Plaque Assay Protocol</title>
<p id="P9">Antiviral activity was determined by the degree of inhibition of viral cytopathic effect (CPE). Briefly, Vero E6 cells were seeded at a density of 3×10<sup>6</sup> cells/96-well plate (ca. 3×10<sup>4</sup> per well) one day before infection. On the day of infection, cells (ca. 80% confluent) were incubated with the compound of interest in the above-mentioned concentration range to a layer of uninfected cells. After 2h of incubating cells with the compound at 37°C in a humidified CO<sub>2</sub> atmosphere, cells were infected with the virus with 100 plaque-forming units (pfu) per well to assess inhibitory effects on virus propagation. One hour post viral infection, cultures were overlayed with 100 μl low-melting agarose. Agarose (Bio-Rad Europe GmbH, Basel, CH), in DMEM/2% FBS was heated to melt and then cooled in a waterbath to a temperature of &lt;40°C, and used to overlay cells in the pre-seeded, infected culture. Then, cells were incubated at 37 °C for approx. 48 h, within which a virus-driven CPE plaque formation is routinely observed in untreated controls. For virus inactivation, 50 μl of formaldehyde (15% w/v) were added for 10 minutes to the cultures without removing the low-melting agarose. After this period, fixative, culture medium and agarose were aspirated, and crystal violet (0.1% w/v) (Sigma-Aldrich) was added to each well and incubated for 5 min. Afterwards, the fixed and stained plates were gently rinsed several times under tap water and dried prior to enumeration. Antiviral activity was determined by the degree of inhibition of viral cytopathic effect (CPE), which became apparent in the form of distinct plaques forming in the cell layer. As the number of plaques observed per well was not easily distinguishable by eye, plates were scanned, and the images were counted as described by Honko et al. [<xref ref-type="bibr" rid="R46">46</xref>] using Image J 1.53k software [<xref ref-type="bibr" rid="R47">47</xref>]. For image processing, images were made binary images according to the Image J definition, the limit to threshold option was enabled under ‘set measurements’ and pixels of the selected area were counted. The results were normalized to positive (virus infected) and negative (DMSO control) controls in each assay plate.</p>
</sec>
<sec id="S7">
<label>2.5</label>
<title>Cytotoxicity Testing</title>
<p id="P10">Vero E6 cells were plated as described above, 3×10<sup>6</sup>/well in 100 μl complete culture medium/2% FBS and cultured overnight. The drug of interest (stock solution) was diluted in DMEM supplemented with 2% FBS, and 50 μl was then added per well (in duplicates or triplicates at the indicated final concentration). The plates were cultured for 48 h, similar to the duration of the infections, after which they were fixed and stained with crystal violet as described above. Cytotoxic effects were evaluated using Image J as described above.</p>
</sec>
<sec id="S8">
<label>2.6</label>
<title>Statistics</title>
<p id="P11">Compounds were tested in duplicates or triplicates per experiment, each experiment was repeated at least twice. Antiviral data were fitted to a sigmoidal curve and a four parameter logistic model was used to calculate IC<sub>50</sub> values using the equation: Y=Bottom + (Top-Bottom)/(1+10<sup>^</sup>((LogIC50-X)*HillSlope)). The IC<sub>50</sub> values are reported at 95% confidence intervals. This analysis was performed using GraphPad Prism v.9.2.0 (San Diego, USA).</p>
</sec>
</sec>
<sec id="S9" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="S10">
<label>3.1</label>
<title>Inhibition Assay of Remdesivir, Ze 339, Petasin, Isopetasin and Neopetasin against the original SARS-CoV-2 Wuhan variant</title>
<p id="P12">In this study, the potent antiviral effects of the <italic>Petasites hybridus</italic> CO<sub>2</sub>-extract Ze 339 as well as its’ active compounds isopetasin and neopetasin (<xref ref-type="fig" rid="F1">Figure 1</xref>) against SARS-CoV-2 infection of the Vero E6 cell line (derived from primary embryonic monkey kidney epithelial cells) was demonstrated.</p>
<p id="P13">The antiviral activity of the test compounds was assessed as previously described [<xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R48">48</xref>] by visualization of the extent of the cytopathogenic effect (CPE) in the form of cytolytic plaque formation on Vero E6 cells when infected with a clinical strain of SARS-CoV-2, Wuhan. Vero E6 cells are stable cell lines expressing a high level of the ACE2 receptor [<xref ref-type="bibr" rid="R49">49</xref>]. They were recently employed in studies to assess SARS-CoV-2 infection and replication by quantifying the virally induced CPE leading to the formation of cytolytic plaques [<xref ref-type="bibr" rid="R50">50</xref>–<xref ref-type="bibr" rid="R53">53</xref>]. Prior to antiviral testing the cytotoxicity of all samples towards Vero E6 cells was assessed, and the 50% cytotoxic concentration (CC<sub>50</sub>) of the test compounds was determined. In addition, a selectivity index (SI) was determined as CC<sub>50</sub>/IC<sub>50</sub>.</p>
<p id="P14">As shown in <xref ref-type="fig" rid="F2">Figure 2</xref> &amp; <xref ref-type="fig" rid="F3">3</xref>, Ze 339 as well as petasin, isopetasin and neopetasin did not show any cytotoxic effect in this assay format up to concentrations of 20 μg/ml (63.2 μM for the petasines, respectively).</p>
<p id="P15">To investigate whether the <italic>P. hybridus</italic> CO<sub>2</sub>-extract Ze 339 and its main active components petasin, isopetasin and neopetasin exert antiviral activity, Vero E6 cells, infected with the Wuhan variant of SARS-CoV-2 were incubated for 48h in the presence of Ze 339 (0.001-20 μg/ml) or the petasines (0.001-20 μg/ml, corresponding to 0.0031-63.2 μM), respectively. The results demonstrated that Ze 339 (<xref ref-type="fig" rid="F2">Figure 2</xref>) inhibited the formation of virus-driven cytopathic changes in a dose-dependent manner in infected Vero E6 cells with an IC<sub>50</sub> of 0.12 μg/ml (C.I. 0.06-0.12). The antiviral drug remdesivir was used as reference and showed anti-SARS-CoV-2 activity with an IC50 of 2.37 μM (C.I. 0.25-0.51) (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<p id="P16">Similar IC<sub>50</sub> values ranging between 1-11 μM for remdesivir have been reported in the literature [<xref ref-type="bibr" rid="R51">51</xref>, <xref ref-type="bibr" rid="R52">52</xref>, <xref ref-type="bibr" rid="R54">54</xref>]. Compared to remdesivir, isopetasin and neopetasin also exerted potent antiviral activities with IC<sub>50</sub> values ranging from 0.79 μM – 1.2 μM (<xref ref-type="fig" rid="F3">Figure 3</xref>). For petasin an IC<sub>50</sub> of 10.79 μM was determined, which was higher than that of isopetasin and neopetasin. However, in aqueous solution petasin converts quickly to its more stable stereoisomer isopetasin. According to a recent screening of 5,632 compounds (natural products as well as synthetics), including 3,488 compounds that have undergone clinical stage testing across 600 indications, only 19 compounds were identified as having an IC<sub>50</sub> in the nanomolar (&lt;1 μM) range, when tested against SARS-CoV-2 in Caco-2 cells [<xref ref-type="bibr" rid="R55">55</xref>]. Among those compounds tested were nafamostat and camostat which have different mechanisms of antiviral action [<xref ref-type="bibr" rid="R55">55</xref>]. The potent anti-SARS-CoV-2 activity of isopetasin and neopetasin is therefore promising. However, further steps are necessary to evaluate the precise underlying mechanism of the antiviral action.</p>
<p id="P17">The selectivity index (SI) of a compound is a commonly used metric to express a compound’s <italic>in vitro</italic> efficacy in inhibiting virus reproduction and an important measure to compare the antiviral efficacy of experimental drugs [<xref ref-type="bibr" rid="R56">56</xref>]. The greater the SI ratio, the more successful and safe a medicine should be for treating a viral infection <italic>in vivo</italic>. The ideal medicine would be cytotoxic at high doses but antiviral at very low concentrations, resulting in a high SI value and the ability to remove the target virus at concentrations much below its cytotoxic concentration. In our study, Ze 339 showed an SI of 200, compared to an SI of 21.1 for remdesivir; the SI for Isopetasin is 80 and for neopetasin 50 when tested against the Wuhan virus variant. Petasin had the lowest SI value but as mentioned above, the values for petasin are likely to be affected by a rapid isomerization. It is noteworthy to mention that compared to remdesivir, Ze 339 as well as isopetasin and neopetasin exerted a higher selectivity index. This is in so far of importance since a vast majority of drug candidates, including repurposed drugs, being currently evaluated as COVID-19 treatments, have SIs that are much lower than that achieved by Ze 339 or the petasines [<xref ref-type="bibr" rid="R57">57</xref>].</p>
</sec>
<sec id="S11">
<label>3.1</label>
<title>Inhibition Assay of Remdesivir, Ze 339 and Isopetasin against the SARS-CoV-2 Delta variant</title>
<p id="P18">As novel SARS-CoV-2 variants of clinical concern spontaneously develop around the world, we tested the antiviral activity of Ze 339 and isopetasin also against the currently dominant SARS-CoV-2 Delta variant. In a first proof of concept experiment, the effect of Ze 339 as well as isopetasin were investigated in the plaque reduction assay when added to the cells prior to infection with the Delta variant. For this experiment, only isopetasin was chosen of the petasins since it is the most stable isomer and since it exerted the lowest IC<sub>50</sub> value when tested against the Wuhan variant. After infection of Vero E6 cells with the Delta virus variant, Ze 339 showed a slightly lower antiviral activity with an IC<sub>50</sub> of 0.40 μg/ml and isopetasin with an IC<sub>50</sub> of 0.28 μg/ml (0.88 μM) (<xref ref-type="fig" rid="F4">Figure 4</xref>). A comparable SARS-CoV-2 inhibitory activity of isopetasin and remdesivir against the Delta variant was observed in this infection experiment. When compared to the Wuhan variant, the activity of Ze 339 and isopetasin against the Delta variant were comparable.</p>
</sec>
</sec>
<sec id="S12" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p id="P19">Facing a globally rapidly expanding new disease such as COVID-19, drug repurposing of existing moieties appears to be a very favorable approach as their development process to drug approval can utilize pre-existing preclinical and often clinical or post-marketing data [<xref ref-type="bibr" rid="R55">55</xref>, <xref ref-type="bibr" rid="R58">58</xref>].</p>
<p id="P20">The current study demonstrates that Ze 339, isopetasin as well as neopetasin were able to potently protect cells from SARS-CoV-2 infection. The antiviral activity of Ze 339 (IC<sub>50</sub> 0.10 μg/ml) against the initial Wuhan strain clearly exceeded that of remdesivir (IC<sub>50</sub> 1.42 μg/ml). Similar potencies were observed for the Delta variant, were Ze 339 protected cells from an SARS-CoV-2_D infection with an IC<sub>50</sub> of 0.40 μg/ml (remdesivir: IC<sub>50</sub> of 0.91 μg/ml). The experiments with isolated petasins suggest that the antiviral effect of Ze 339 is due to the sum of petasins.</p>
<p id="P21">Easy to use and affordable COVID-19 therapies are urgently needed for clinical disease management. A great advantage of Ze 339 therefore is that it already is an approved OTC drug in Switzerland and various other countries for oral treatment of seasonal allergic rhinitis. Further, Ze 339 is available for self-medication. Clinical and postmarketing surveillance studies did not reveal any safety concerns [<xref ref-type="bibr" rid="R59">59</xref>–<xref ref-type="bibr" rid="R63">63</xref>]. The range and incidence of adverse effects in the respective studies were very low; described adverse events had all previously been known and are included in the summary of product characteristics [<xref ref-type="bibr" rid="R64">64</xref>]. Furthermore, as an approved drug, Ze 339 is subject to pharmacovigilance activities according to current standard procedures. The lack of safety findings reported for <italic>P. hybridus</italic> extract Ze 339 reflects the fairly robust overall safety assessment from clinical experience exceeding 15 years since marketing authorization.</p>
<p id="P22">In addition, the mechanism of action as well as the active compounds of Ze 339 have been well-described. From a range of pharmacological studies, Ze 339 and its active constituents, petasin and its isomers iso- and neopetasin, have been shown to ultimately inhibit the synthesis of leukotrienes in human target cells such as leukocytes and macrophages cultured <italic>in vitro</italic> or ex <italic>vivo</italic> [<xref ref-type="bibr" rid="R39">39</xref>–<xref ref-type="bibr" rid="R41">41</xref>, <xref ref-type="bibr" rid="R65">65</xref>]. Moreover, Ze 339 has been shown to reduce TNF-α, IL-6 and IL-8 levels in human nasal epithelial cells challenged with viral mimetics [<xref ref-type="bibr" rid="R42">42</xref>].</p>
<p id="P23">Furthermore, in addition to the above mentioned mechanisms of action, petasin is also a potent activator of the AMP-activated protein kinase (AMPK) [<xref ref-type="bibr" rid="R66">66</xref>]. AMPK impairs SARS-CoV-2 replication in several ways: activated AMPK phosphorylates angiotensin-converting enzyme 2 and decreases SARS-CoV-2 binding to the enzyme, thereby decreasing cellular uptake of the virus [<xref ref-type="bibr" rid="R67">67</xref>]. Activated AMPK also suppresses the protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) pathway, which is required for viral protein translation and replication [<xref ref-type="bibr" rid="R68">68</xref>]. This is consistent with previous clinical data showing an improved mortality in diabetic COVID-19 patients trerated with the indirekt AMPK activator metformin [<xref ref-type="bibr" rid="R69">69</xref>–<xref ref-type="bibr" rid="R71">71</xref>]. Finally, metformin suppresses inflammatory pathways and immunological responses (cytokine storms) [<xref ref-type="bibr" rid="R72">72</xref>].</p>
<p id="P24">It is further worth mentioning that the mechanism of anti-inflammatory action of Ze 339 is comparable to that of montelukast and zileuton, which are currently under discussion as therapeutic candidates for the treatment of COVID-19 [<xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R29">29</xref>]. In a recent study by Durdagi et al. [<xref ref-type="bibr" rid="R73">73</xref>] demonstrated the neutralization effect of montelukast on SARS-CoV-2 <italic>in vitro</italic> by showing that virus replication could be significantly delayed. The authors suggested to consider montelukast for prophylactic treatment. In our current study, a pre-incubation of cells with the test compounds for 2 h prior to virus infection had a clear positive effect, suggesting a possible prophylactic role also for the petasins. While the montelukast IC<sub>50</sub> values were at 18.82 μM and 25 μM in <italic>in vitro</italic> cell culture models of SARS-CoV-2 activity [<xref ref-type="bibr" rid="R73">73</xref>, <xref ref-type="bibr" rid="R74">74</xref>], the IC<sub>50</sub>s for Ze 339, isopetasin and neopetasin determined in the current study were significantly lower. The visibly shallower inhibition curves of the petasin compounds compared to the antiviral mechanism of remdesivir could suggest a more complex mode of interference with the viral life cycle which is supported by the above mentioned various mechanisms of action of Ze 339. A similar difference is also been observed for different HIV inhibitor classes (e.g. nucleosidic polymerase inhibitors versus protease inhibitors; not shown).</p>
</sec>
<sec id="S13" sec-type="conclusions">
<label>5</label>
<title>Conclusions</title>
<p id="P25">In conclusion, since affordable therapies for treating SARS-CoV-2 infection and COVID-19 are urgently needed, we propose that Ze 339 could be a promising candidate for drug repurposing with a supposed dual mode of action through a direct anti-SARS-CoV2 effect and a potent indirect inhibitory effect on leukotriene biosynthesis/cytokine activity or AMPK activation.</p>
<p id="P26">Taken together, the <italic>Petasites hybridus</italic> subcritical CO<sub>2</sub>-extract Ze 339 may provide a safe, low-cost alternative for treating patients infected with SARS CoV-2. As Ze 339 is registered in Switzerland as OTC drug, it is a promising repurposing candidate due to its proven safety profile. For further development, the current <italic>in vitro</italic> data will have to be verified <italic>in vivo</italic>, and a clinical benefit of Ze 339 as a possible drug for treating mild to moderate cases of COVID-19 needs to be proven in future clinical studies.</p>
<p id="P27">Supplementary Materials: Figure S1: A GC chromatogram of Ze 339 is shown in Figure S1.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Material</label>
<media xlink:href="EMS141076-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="N66524" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S14">
<title>Acknowledgement</title>
<p>For providing access to the SARS-CoV-2 strain /NL/2020 – AMS, we thank the EVA GLOBAL consortium (funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 871029) and Dr. B. Hagman.</p>
<sec id="S15">
<title>Funding</title>
<p>The study was funded by Max Zeller Soehne AG, CH-8590 Romanshorn, Switzerland</p>
</sec>
</ack>
<sec id="S16" sec-type="data-availability">
<title>Data Availability Statement</title>
<p id="P28">Data are available on request from the authors.</p>
</sec>
<fn-group>
<fn id="FN1" fn-type="con">
<p id="P29">
<bold>Author Contributions</bold>
</p>
<p id="P30">The following statements should be used “Conceptualization, T.K., M.K., V.B. and J.D; methodology, L.U.; software L.U., V.B.; formal analysis, V.B.; G.B. writing—original draft preparation, V.B.; G.B., T.K. writing—review and editing, J.D.; visualization, V.B.; supervision, T.K.;. All authors have read and agreed to the published version of the manuscript.”</p>
</fn>
<fn id="FN2" fn-type="conflict">
<p id="P31">
<bold>Conflicts of Interest</bold>
</p>
<p id="P32">MK, VB, JD and GB are employees of Max Zeller Soehne AG, CH-8590 Romanshorn, Switzerland, the manufacturer of Ze 339. Max Zeller Soehne AG is the sponsor of this study.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="web">
<collab>Center C V R</collab>
<source>COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)</source>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/map.html">https://coronavirus.jhu.edu/map.html</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tizaoui</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zidi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Ghayda</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Koyanagi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kronbichler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>JI</given-names>
</name>
</person-group>
<article-title>Update of the current knowledge on genetics, evolution, immunopathogenesis, and transmission for coronavirus disease 19 (COVID-19)</article-title>
<source>Int J Biol Sci</source>
<year>2020</year>
<volume>16</volume>
<issue>15</issue>
<fpage>2906</fpage>
<lpage>2923</lpage>
<pub-id pub-id-type="doi">10.7150/ijbs.48812</pub-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>England</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Abdulla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Biggs</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>AYY</given-names>
</name>
<name>
<surname>Hay</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Wellington</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Sekhon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jamal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shojania</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>LYC</given-names>
</name>
</person-group>
<article-title>Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes</article-title>
<source>Blood Rev</source>
<year>2021</year>
<volume>45</volume>
<elocation-id>100707</elocation-id>
<pub-id pub-id-type="doi">10.1016/j.blre.2020.100707</pub-id>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>DS</given-names>
</name>
</person-group>
<article-title>Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China</article-title>
<source>Clin Infect Dis</source>
<year>2020</year>
<volume>71</volume>
<issue>15</issue>
<fpage>762</fpage>
<lpage>768</lpage>
<pub-id pub-id-type="doi">10.1093/cid/ciaa248</pub-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clark</surname>
<given-names>IA</given-names>
</name>
</person-group>
<article-title>The advent of the cytokine storm</article-title>
<source>Immunol Cell Biol</source>
<year>2007</year>
<volume>85</volume>
<issue>4</issue>
<fpage>271</fpage>
<lpage>3</lpage>
<pub-id pub-id-type="doi">10.1038/sj.icb.7100062</pub-id>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jose</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Manuel</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>COVID-19 cytokine storm: the interplay between inflammation and coagulation</article-title>
<source>Lancet Respir Med</source>
<year>2020</year>
<volume>8</volume>
<issue>6</issue>
<fpage>e46</fpage>
<lpage>e47</lpage>
<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30216-2</pub-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carsana</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sonzogni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nasr</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Pellegrinelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zerbi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rech</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Colombo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Antinori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Corbellino</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Galli</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study</article-title>
<source>Lancet Infect Dis</source>
<year>2020</year>
<volume>20</volume>
<issue>10</issue>
<fpage>1135</fpage>
<lpage>1140</lpage>
<pub-id pub-id-type="doi">10.1016/S1473-3099(20)30434-5</pub-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grasselli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tonetti</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Protti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Langer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Girardis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bellani</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Laffey</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Carrafiello</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Carsana</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rizzuto</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zanella</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>collaborators, Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study</article-title>
<source>Lancet Respir Med</source>
<year>2020</year>
<volume>8</volume>
<issue>12</issue>
<fpage>1201</fpage>
<lpage>1208</lpage>
<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30370-2</pub-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sonzogni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Previtali</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Seghezzi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grazia Alessio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gianatti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Licini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Morotti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zerbi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Carsana</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lauri</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<article-title>Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations</article-title>
<source>Liver Int</source>
<year>2020</year>
<volume>40</volume>
<issue>9</issue>
<fpage>2110</fpage>
<lpage>2116</lpage>
<pub-id pub-id-type="doi">10.1111/liv.14601</pub-id>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maiuolo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mollace</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gliozzi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Musolino</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Carresi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Paone</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Scicchitano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Macri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nucera</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bosco</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Scarano</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<article-title>The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection</article-title>
<source>Int J Mol Sci</source>
<year>2020</year>
<volume>21</volume>
<issue>23</issue>
<pub-id pub-id-type="doi">10.3390/ijms21239309</pub-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Combes</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Courau</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>NF</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Chew</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Cleary</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Kushnoor</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Reeder</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Global absence and targeting of protective immune states in severe COVID-19</article-title>
<source>Nature</source>
<year>2021</year>
<volume>591</volume>
<issue>7848</issue>
<fpage>124</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1038/s41586-021-03234-7</pub-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodríguez</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Luque</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Blanco</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Sebastian</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Barbera</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Peinado</surname>
<given-names>VI</given-names>
</name>
<name>
<surname>Tura-Ceide</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Pulmonary Endothelial Dysfunction and Thrombotic Complications in Patients with COVID-19</article-title>
<source>Am J Respir Cell Mol Biol</source>
<year>2021</year>
<volume>64</volume>
<issue>4</issue>
<fpage>407</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="doi">10.1165/rcmb.2020-0359PS</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>The signal pathways and treatment of cytokine storm in COVID-19</article-title>
<source>Signal Transduct Target Ther</source>
<year>2021</year>
<volume>6</volume>
<issue>1</issue>
<fpage>255</fpage>
<pub-id pub-id-type="doi">10.1038/s41392-021-00679-0</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Couzin-Frankel</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Antiviral pills could change pandemic’s course</article-title>
<source>Science</source>
<year>2021</year>
<volume>374</volume>
<issue>6569</issue>
<fpage>799</fpage>
<lpage>800</lpage>
<pub-id pub-id-type="doi">10.1126/science.acx9605</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design</article-title>
<source>Med Res Rev</source>
<year>2021</year>
<volume>41</volume>
<issue>4</issue>
<fpage>1965</fpage>
<lpage>1998</lpage>
<pub-id pub-id-type="doi">10.1002/med.21783</pub-id>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="web">
<source>Pfizer Pfizer Press Release: PFIZER INITIATES PHASE 1 STUDY OF NOVEL ORAL ANTIVIRAL THERAPEUTIC AGENT AGAINST SARS-COV-2</source>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-1-study-novel-oral-antiviral">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-1-study-novel-oral-antiviral</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Group</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Horby</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Emberson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Mafham</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Linsell</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Staplin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Brightling</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ustianowski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Elmahi</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<article-title>Dexamethasone in Hospitalized Patients with Covid-19</article-title>
<source>N Engl J Med</source>
<year>2021</year>
<volume>384</volume>
<issue>8</issue>
<fpage>693</fpage>
<lpage>704</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa2021436</pub-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahase</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint</article-title>
<source>BMJ</source>
<year>2020</year>
<volume>369</volume>
<elocation-id>m2512</elocation-id>
<pub-id pub-id-type="doi">10.1136/bmj.m2512</pub-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olender</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Go</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Balani</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Price-Haywood</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Walunas</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Swaminathan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Slim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chin</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care</article-title>
<source>Clin Infect Dis</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1093/cid/ciaal041</pub-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olender</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Walunas</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Castagna</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kurbegov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Goyal</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ripamonti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Balani</surname>
<given-names>B</given-names>
</name>
<name>
<surname>De Rosa</surname>
<given-names>FG</given-names>
</name>
<etal/>
</person-group>
<article-title>Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality</article-title>
<source>Open Forum Infect Dis</source>
<year>2021</year>
<volume>8</volume>
<issue>7</issue>
<elocation-id>ofab278</elocation-id>
<pub-id pub-id-type="doi">10.1093/ofid/ofab278</pub-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spinner</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Gottlieb</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Criner</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Arribas Lopez</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Cattelan</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Soriano Viladomiu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ogbuagu</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Malhotra</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mullane</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Castagna</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>LYA</given-names>
</name>
<etal/>
</person-group>
<article-title>Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial</article-title>
<source>JAMA</source>
<year>2020</year>
<volume>324</volume>
<issue>11</issue>
<fpage>1048</fpage>
<lpage>1057</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2020.16349</pub-id>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>QY</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>CX</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>JY</given-names>
</name>
</person-group>
<article-title>Remdesivir and COVID-19</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>396</volume>
<issue>10256</issue>
<fpage>953</fpage>
<lpage>954</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)32019-5</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>395</volume>
<issue>10236</issue>
<fpage>1569</fpage>
<lpage>1578</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)31022-9</pub-id>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial</article-title>
<source>Trials</source>
<year>2020</year>
<volume>21</volume>
<issue>1</issue>
<fpage>422</fpage>
<pub-id pub-id-type="doi">10.1186/s13063-020-04352-9</pub-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Almerie</surname>
<given-names>MQ</given-names>
</name>
<name>
<surname>Kerrigan</surname>
<given-names>DD</given-names>
</name>
</person-group>
<article-title>The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast</article-title>
<source>Med Hypotheses</source>
<year>2020</year>
<volume>143</volume>
<elocation-id>109883</elocation-id>
<pub-id pub-id-type="doi">10.1016/j.mehy.2020.109883</pub-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bozek</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Winterstein</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Montelukast’s ability to fight COVID-19 infection</article-title>
<source>J Asthma</source>
<year>2021</year>
<volume>58</volume>
<issue>10</issue>
<fpage>1348</fpage>
<lpage>1349</lpage>
<pub-id pub-id-type="doi">10.1080/02770903.2020.1786112</pub-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Funk</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Ardakani</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes</article-title>
<source>Front Pharmacol</source>
<year>2020</year>
<volume>11</volume>
<elocation-id>1214</elocation-id>
<pub-id pub-id-type="doi">10.3389/fphar.2020.01214</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fidan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Aydogdu</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>As a potential treatment of COVID-19: Montelukast</article-title>
<source>Med Hypotheses</source>
<year>2020</year>
<volume>142</volume>
<elocation-id>109828</elocation-id>
<pub-id pub-id-type="doi">10.1016/j.mehy.2020.109828</pub-id>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Citron</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Perelli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Deem</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Genovese</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Viale</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Leukotrienes, a potential target for Covid-19</article-title>
<source>Prostaglandins Leukot Essent Fatty Acids</source>
<year>2020</year>
<volume>161</volume>
<elocation-id>102174</elocation-id>
<pub-id pub-id-type="doi">10.1016/j.plefa.2020.102174</pub-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Archambault</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Zaid</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Rakotoarivelo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Turcotte</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dore</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dubuc</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Flamand</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Amar</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cheikh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fares</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients</article-title>
<source>FASEB J</source>
<year>2021</year>
<volume>35</volume>
<issue>6</issue>
<elocation-id>e21666</elocation-id>
<pub-id pub-id-type="doi">10.1096/fj.202100540R</pub-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaid</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Dore</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dubuc</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Archambault</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Flamand</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Laviolette</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Flamand</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Boilard</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Flamand</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19</article-title>
<source>J Allergy Clin Immunol</source>
<year>2021</year>
<volume>148</volume>
<issue>2</issue>
<fpage>368</fpage>
<lpage>380</lpage>
<elocation-id>e3</elocation-id>
<pub-id pub-id-type="doi">10.1016/j.jaci.2021.05.032</pub-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Funk</surname>
<given-names>CD</given-names>
</name>
</person-group>
<article-title>Prostaglandins and leukotrienes: advances in eicosanoid biology</article-title>
<source>Science</source>
<year>2001</year>
<volume>294</volume>
<issue>5548</issue>
<fpage>1871</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1126/science.294.5548.1871</pub-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanaoka</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Boyce</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses</article-title>
<source>J Immunol</source>
<year>2004</year>
<volume>173</volume>
<issue>3</issue>
<fpage>1503</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.173.3.1503</pub-id>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Werz</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Steinhilber</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Therapeutic options for 5-lipoxygenase inhibitors</article-title>
<source>Pharmacol Ther</source>
<year>2006</year>
<volume>112</volume>
<issue>3</issue>
<fpage>701</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2006.05.009</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Mohammed</surname>
<given-names>LA</given-names>
</name>
</person-group>
<article-title>The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets?</article-title>
<source>Inflammopharmacology</source>
<year>2006</year>
<volume>14</volume>
<issue>1-2</issue>
<fpage>10</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1007/s10787-006-1496-6</pub-id>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Tandon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dastidar</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>A review on leukotrienes and their receptors with reference to asthma</article-title>
<source>J Asthma</source>
<year>2013</year>
<volume>50</volume>
<issue>9</issue>
<fpage>922</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.3109/02770903.2013.823447</pub-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brattström</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>A newly developed extract (Ze 339) from butterbur (Petasites hybridus L.) is clinically efficient in allergic rhinitis (hay fever)</article-title>
<source>Phytomedicine</source>
<year>2003</year>
<volume>10</volume>
<issue>Suppl 4</issue>
<fpage>50</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="doi">10.1078/1433-187x-00304</pub-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kodjadjiku</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Nagele</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Halbsguth</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Butterweck</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Extract matrix composition does not affect in vitro leukotriene inhibitory effects of the Petasites hybridus extract Ze 339</article-title>
<source>Fitoterapia</source>
<year>2021</year>
<volume>153</volume>
<elocation-id>104986</elocation-id>
<pub-id pub-id-type="doi">10.1016/j.fitote.2021.104986</pub-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomet</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Schapowal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heinisch</surname>
<given-names>IV</given-names>
</name>
<name>
<surname>Wiesmann</surname>
<given-names>UN</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>HU</given-names>
</name>
</person-group>
<article-title>Antiinflammatory activity of an extract of Petasites hybridus in allergic rhinitis</article-title>
<source>Int Immunopharmacol</source>
<year>2002</year>
<volume>2</volume>
<issue>7</issue>
<fpage>997</fpage>
<lpage>1006</lpage>
<pub-id pub-id-type="doi">10.1016/sl567-5769(02)00046-2</pub-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomet</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Wiesmann</surname>
<given-names>UN</given-names>
</name>
<name>
<surname>Blaser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>HU</given-names>
</name>
</person-group>
<article-title>Differential inhibition of inflammatory effector functions by petasin, isopetasin and neopetasin in human eosinophils</article-title>
<source>Clin Exp Allergy</source>
<year>2001</year>
<volume>31</volume>
<issue>8</issue>
<fpage>1310</fpage>
<lpage>20</lpage>
<comment>DOI: ceall58 [pii]</comment>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomet</surname>
<given-names>OAR</given-names>
</name>
<name>
<surname>Wiesmann</surname>
<given-names>UN</given-names>
</name>
<name>
<surname>Schapowal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bizer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>H-U</given-names>
</name>
</person-group>
<article-title>Role of petasin in the potential anti-inflammatory activity of a plant extract of Petasites hybridus</article-title>
<source>Biochemical pharmacology</source>
<year>2001</year>
<volume>61</volume>
<issue>8</issue>
<fpage>1041</fpage>
<lpage>1047</lpage>
<pub-id pub-id-type="doi">10.1016/s0006-2952(01)00552-4</pub-id>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steiert</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Zissler</surname>
<given-names>UM</given-names>
</name>
<name>
<surname>Chaker</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Esser-von-Bieren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dittlein</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Guerth</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jakwerth</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Piontek</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zahner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Drewe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Traidl-Hoffmann</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Anti-inflammatory effects of the petasin phyto drug Ze339 are mediated by inhibition of the STAT pathway</article-title>
<source>Biofactors</source>
<year>2017</year>
<volume>43</volume>
<issue>3</issue>
<fpage>388</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="doi">10.1002/biof.1349</pub-id>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Koch</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Rittinghausen</surname>
<given-names>R</given-names>
</name>
</person-group>
<source>Composition containing pyrrolizidine-alkaloid-free Petasites</source>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://patents.google.com/patent/US655l626Bl/en">https://patents.google.com/patent/US655l626Bl/en</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Steiner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hauk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tratz</surname>
<given-names>W</given-names>
</name>
</person-group>
<source>Method for Producing Medicinal Plant Extracts</source>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://patentimages.storage.googleapis.com/2e/83/fc/24cllflf7be22c/WO1999018984Al.pdf">https://patentimages.storage.googleapis.com/2e/83/fc/24cllflf7be22c/WO1999018984Al.pdf</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corman</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Landt</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kaiser</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Molenkamp</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Meijer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Bleicker</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Brunink</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Mulders</surname>
<given-names>DG</given-names>
</name>
<etal/>
</person-group>
<article-title>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</article-title>
<source>Euro Surveill</source>
<year>2020</year>
<volume>25</volume>
<issue>3</issue>
<pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.3.2000045</pub-id>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Honko</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Storm</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bean</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Henao Vasquez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Downs</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Griffiths</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Rapid Quantification and Neutralization Assays for Novel Coronavirus SARS-CoV-2 Using Avicel RC-591 Semi-Solid Overlay</article-title>
<source>Preprints</source>
<year>2020</year>
<elocation-id>2020050264</elocation-id>
<pub-id pub-id-type="doi">10.20944/preprints202005.0264.vl</pub-id>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Rasband</surname>
<given-names>WS</given-names>
</name>
</person-group>
<source>Image J</source>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://imagei.nih.gov/ij/">https://imagei.nih.gov/ij/</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kehn-Hall</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Viral concentration determination through plaque assays: using traditional and novel overlay systems</article-title>
<source>J Vis Exp</source>
<year>2014</year>
<issue>93</issue>
<elocation-id>e52065</elocation-id>
<pub-id pub-id-type="doi">10.3791/52065</pub-id>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Jan</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Juan</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Brik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>FS</given-names>
</name>
<etal/>
</person-group>
<article-title>Small molecules targeting severe acute respiratory syndrome human coronavirus</article-title>
<source>Proc Natl Acad SciUSA</source>
<year>2004</year>
<volume>101</volume>
<issue>27</issue>
<fpage>10012</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0403596101</pub-id>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Olukitibi</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Mahmoudi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kobasa</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Identification and evaluation of the inhibitory effect of Prunella vulgaris extract on SARS-coronavirus 2 virus entry</article-title>
<source>PLoS One</source>
<year>2021</year>
<volume>16</volume>
<issue>6</issue>
<elocation-id>e0251649</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0251649</pub-id>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Byun</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shum</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs</article-title>
<source>Antimicrob Agents Chemother</source>
<year>2020</year>
<volume>64</volume>
<issue>7</issue>
<pub-id pub-id-type="doi">10.1128/AAC.00819-20</pub-id>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ku</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2</article-title>
<source>J Microbiol Biotechnol</source>
<year>2020</year>
<volume>30</volume>
<issue>12</issue>
<fpage>1843</fpage>
<lpage>1853</lpage>
<pub-id pub-id-type="doi">10.4014/jmb.2009.09009</pub-id>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nao</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shirato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kawase</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takayama</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Nagata</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sekizuka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sakata</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells</article-title>
<source>Proc Natl Acad Sci U SA</source>
<year>2020</year>
<volume>117</volume>
<issue>13</issue>
<fpage>7001</fpage>
<lpage>7003</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.2002589117</pub-id>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tietjen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cassel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Register</surname>
<given-names>ET</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>XY</given-names>
</name>
<name>
<surname>Messick</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Keeney</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Beattie</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Rali</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tebas</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ertl</surname>
<given-names>HCJ</given-names>
</name>
<etal/>
</person-group>
<article-title>The natural stilbenoid (-)-hopeaphenol inhibits cellular entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7 and B.1.351 variants</article-title>
<source>Antimicrob Agents Chemother</source>
<year>2021</year>
<elocation-id>AAC0077221</elocation-id>
<pub-id pub-id-type="doi">10.1128/AAC.00772-21</pub-id>
</element-citation>
</ref>
<ref id="R55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ellinger</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bojkova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zaliani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cinatl</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Claussen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Westhaus</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Keminer</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Reinshagen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kuzikov</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Geisslinger</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>
<article-title>A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection</article-title>
<source>Sci Data</source>
<year>2021</year>
<volume>8</volume>
<issue>1</issue>
<fpage>70</fpage>
<pub-id pub-id-type="doi">10.1038/s41597-021-00848-4</pub-id>
</element-citation>
</ref>
<ref id="R56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Indrayanto</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Putra</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Suhud</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Validation of in-vitro bioassay methods: Application in herbal drug research</article-title>
<source>Profiles Drug Subst Excip Relat Methodol</source>
<year>2021</year>
<volume>46</volume>
<fpage>273</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="doi">10.1016/bs.podrm.2020.07.005</pub-id>
</element-citation>
</ref>
<ref id="R57">
<label>57</label>
<element-citation publication-type="web">
<source>Targeting COVID-l9:GHDDI Info Sharing Portal, COVID-19 preclinical studies</source>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://ghddi-ailab.github.io/Targeting2Ol9-nCoV/preclinical/">https://ghddi-ailab.github.io/Targeting2Ol9-nCoV/preclinical/</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dittmar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Whig</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Segrist</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kamalia</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Castellana</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ayyanathan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cardenas-Diaz</surname>
<given-names>FL</given-names>
</name>
<name>
<surname>Morrisey</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Truitt</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2</article-title>
<source>Cell Rep</source>
<year>2021</year>
<volume>35</volume>
<issue>1</issue>
<elocation-id>108959</elocation-id>
<pub-id pub-id-type="doi">10.1016/j.celrep.2021.108959</pub-id>
</element-citation>
</ref>
<ref id="R59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blosa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Uricher</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nebel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zahner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Butterweck</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Drewe</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Treatment of Early Allergic and Late Inflammatory Symptoms of Allergic Rhinitis with Petasites hybridus Leaf Extract (Ze 339): Results of a Noninterventional Observational Study in Switzerland</article-title>
<source>Pharmaceuticals</source>
<year>2021</year>
<volume>14</volume>
<issue>3</issue>
<pub-id pub-id-type="doi">10.3390/phl4030180</pub-id>
</element-citation>
</ref>
<ref id="R60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dumitru</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Shamji</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wagenmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hindersin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Scheckenbach</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Greve</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Klenzner</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hess</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nebel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zimmermann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zahner</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine</article-title>
<source>J Allergy Clin Immunol</source>
<year>2011</year>
<volume>127</volume>
<issue>6</issue>
<fpage>1515</fpage>
<lpage>21</lpage>
<elocation-id>e6</elocation-id>
<pub-id pub-id-type="doi">10.1016/j.jaci.2011.02.045</pub-id>
</element-citation>
</ref>
<ref id="R61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schapowal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Petasites Study</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis</article-title>
<source>BMJ</source>
<year>2002</year>
<volume>324</volume>
<issue>7330</issue>
<fpage>144</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1136/bmj.324.7330.144</pub-id>
</element-citation>
</ref>
<ref id="R62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schapowal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Petasites Study</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Butterbur Ze339 for the treatment of intermittent allergic rhinitis: dose-dependent efficacy in a prospective, randomized, double-blind, placebo-controlled study</article-title>
<source>Arch Otolaryngol Head Neck Surg</source>
<year>2004</year>
<volume>130</volume>
<issue>12</issue>
<fpage>1381</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1001/archotol.130.12.1381</pub-id>
</element-citation>
</ref>
<ref id="R63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schapowal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Study</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Treating intermittent allergic rhinitis: a prospective, randomized, placebo and antihistamine-controlled study of Butterbur extract Ze 339</article-title>
<source>Phytother Res</source>
<year>2005</year>
<volume>19</volume>
<issue>6</issue>
<fpage>530</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1002/ptr.1705</pub-id>
</element-citation>
</ref>
<ref id="R64">
<label>64</label>
<element-citation publication-type="web">
<source>Product information, Information for Healthcare Professionals</source>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.swissmedicinfo.ch/?Lang=EN">https://www.swissmedicinfo.ch/?Lang=EN</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomet</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>HU</given-names>
</name>
</person-group>
<article-title>Petasins in the treatment of allergic diseases: results of preclinical and clinical studies</article-title>
<source>Int Arch Allergy Immunol</source>
<year>2002</year>
<volume>129</volume>
<issue>2</issue>
<fpage>108</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1159/000065884</pub-id>
</element-citation>
</ref>
<ref id="R66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adachi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kanbayashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Harata</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ubagai</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Takimoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Miwa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Petasin activates AMP-activated protein kinase and modulates glucose metabolism</article-title>
<source>J Nat Prod</source>
<year>2014</year>
<volume>77</volume>
<issue>6</issue>
<fpage>1262</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1021/np400867m</pub-id>
</element-citation>
</ref>
<ref id="R67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sadasivam</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Metformin in COVID-19: A possible role beyond diabetes</article-title>
<source>Diabetes Res Clin Pract</source>
<year>2020</year>
<volume>164</volume>
<elocation-id>108183</elocation-id>
<pub-id pub-id-type="doi">10.1016/j.diabres.2020.108183</pub-id>
</element-citation>
</ref>
<ref id="R68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karam</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Bramante</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Puskarich</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zolfaghari</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Lotfi-Emran</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ingraham</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Charles</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Odde</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Tignanelli</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses</article-title>
<source>J Med Virol</source>
<year>2021</year>
<volume>93</volume>
<issue>4</issue>
<fpage>1843</fpage>
<lpage>1846</lpage>
<pub-id pub-id-type="doi">10.1002/jmv.26728</pub-id>
</element-citation>
</ref>
<ref id="R69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kow</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Hasan</surname>
<given-names>SS</given-names>
</name>
</person-group>
<article-title>Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis</article-title>
<source>J Med Virol</source>
<year>2021</year>
<volume>93</volume>
<issue>2</issue>
<fpage>695</fpage>
<lpage>697</lpage>
<pub-id pub-id-type="doi">10.1002/jmv.26498</pub-id>
</element-citation>
</ref>
<ref id="R70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lally</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Tsoukas</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Halladay</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gravenstein</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rudolph</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Metformin is Associated with Decreased 30-Day Mortality Among Nursing Home Residents Infected with SARS-CoV2</article-title>
<source>J Am Med Dir Assoc</source>
<year>2021</year>
<volume>22</volume>
<issue>1</issue>
<fpage>193</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="doi">10.1016/j.jamda.2020.10.031</pub-id>
</element-citation>
</ref>
<ref id="R71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nafakhi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Alareedh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Al-Buthabhak</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shaghee</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nafakhi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kasim</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq</article-title>
<source>Diabetes Metab Syndr</source>
<year>2021</year>
<volume>15</volume>
<issue>1</issue>
<fpage>33</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/j.dsx.2020.12.014</pub-id>
</element-citation>
</ref>
<ref id="R72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Leng</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury</article-title>
<source>Front Immunol</source>
<year>2020</year>
<volume>11</volume>
<elocation-id>2056</elocation-id>
<pub-id pub-id-type="doi">10.3389/fimmu.2020.02056</pub-id>
</element-citation>
</ref>
<ref id="R73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durdagi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Avsar</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Orhan</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Serhatli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Balcioglu</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Ozturk</surname>
<given-names>HU</given-names>
</name>
<name>
<surname>Kayabolen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cetin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Aydinlik</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bagci-Onder</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tekin</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>The neutralization effect of montelukaston SARS-CoV-2 is shown by multiscale in silicosimulations and combined in vitro studies</article-title>
<source>Mol Ther</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1016/j.ymthe.2021.10.014</pub-id>
</element-citation>
</ref>
<ref id="R74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kumari</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Agnihotri</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kant Beuria</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Syed</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Dixit</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity</article-title>
<source>Comput Struct Biotechnol J</source>
<year>2021</year>
<volume>19</volume>
<fpage>1998</fpage>
<lpage>2017</lpage>
<pub-id pub-id-type="doi">10.1016/j.csbj.2021.04.014</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Chemical structures of the main petasins from <italic>Petasites hybridus</italic>
</title>
</caption>
<graphic xlink:href="EMS141076-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Anti-SARS-CoV-2 activity of the remdesivir and Ze 339 in VeroE6 cells was assessed using the Wuhan strain of SARS-CoV-2. Cells were infected with 100 pfu of a clinical virus isolate in the presence of the indicated concentrations. Blue squares represent inhibition of SARS-CoV-2 infection (%), red triangles represent cell viability (%). Data are expressed as the mean of two replicates (infection performed in duplicate) with their respected 95% confidence interval. Remdesivir 95% confidence interval = 0.25-0.51, goodness of fit = 0.9668; Ze 339 95% confidence interval = 0.06-0.12, goodness of fit = 0.9962.</p>
</caption>
<graphic xlink:href="EMS141076-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Anti-SARS-CoV-2 activity of the isopetasin and neopetasin in VeroE6 cells was assessed using the Wuhan strain of SARS-CoV-2. Cells were infected with 100 pfu of a clinical virus isolate in the presence of the indicated concentrations. Blue squares represent inhibition of SARS-CoV-2 infection (%), red triangles represent cell viability (%). Data are expressed as the mean of two replicates (performed in duplicate) with their respected 95% confidence interval. Petasin confidence interval = 2.70-4.31, goodness of fit = 0.9874; Isopetasin 95% confidence interval = 0.15-0.41, goodness of fit = 0.9918; neopetasin 95% confidence interval = 0.27-0.55, goodness of fit = 0.9929.</p>
</caption>
<graphic xlink:href="EMS141076-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Dose response curves for remdesivir, Ze 339, and isopetasin on the SARS-CoV-2 Delta variant. Cells were infected with 100 pfu of a clinical virus isolate in the presence of the indicated concentrations. Blue circles represent inhibition of SARS-CoV-2 infection (%). Data are expressed as the mean of duplicate measurements with their respected 95% confidence interval. Ze 339 95% confidence interval 0.26-0.58, goodness of fit = 0.9943, isopetasin 95% confidence interval = 0.21-0.38, goodness of fit = 0.9845.</p>
</caption>
<graphic xlink:href="EMS141076-f004"/>
</fig>
</floats-group>
</article>
